微卡联合化学药物治疗初治肺结核的临床观察  

A clinical trial of Mycobaeterium Vaccae vaccine combining chemotherapy in treating new pulmonary tuberculosis

作　　者：李红[1] 唐神结[1] 

机构地区：[1]上海市肺科医院,上海200433

出　　处：《中国防痨杂志》2006年第4期241-243,共3页Chinese Journal of Antituberculosis

摘　　要：目的观察微卡联合抗结核药物治疗初治菌阳肺结核的临床疗效、不良反应。方法将109例初治菌阳肺结核患者随机分为治疗组:2微卡+HRZE(S)/4微卡+HR 58例,对照组:2HRZE(S)/4HR 51例。结果治疗2周,1、2个月痰菌阴转率治疗组为44.8%、62.0%、89.7%,对照组为25.5%、41.2%、76.0%(P<0.05);治疗2个月末胸片上治疗组与对照组病灶吸收率分别为37.9%、19.6%(P<0.05);空洞闭合率各为65.5%,38.7%(P<0.05);治疗组在治疗2周后临床咳嗽、发热、乏力消失率为48.3%7、1.4%5、9.3%,对照组为25.5%、50.0%、40.0%(P<0.05);无不良反应发生;治疗组在疗程结束后61、22、4个月痰菌复阳率和对照组相比无显著性差异,P>0.05;结论微卡联合抗结核药物在初治菌阳肺结核的治疗上与单用抗结核药物治疗相比缩短了痰菌转阴、胸片病灶吸收和临床症状改善的时间,是较好的结核病免疫治疗制剂。Objective To study the efficacy and adverse reaction of Mycobacterium Vaccae vaccine in treating new smear positive tuberculosis(TB).?Method 109 new smear positive pulmonary TB patients were randomly allocated into treatment group which received 2 M.Vaccae vaccine +HRZE(S)/4 M.Vaccae vaccine +HR (58cases)and control group which received 2HRZE(S)/4HR(51 cases).?Result The sputum negative conversion rate at the second week,the first and second month were 44.8% 62.0%,89.7% in the treatment group and 25.5%,41.2%,76% in the control group respectively;at the second month chest radiography showed the resolution of pulmonary lesions in the treatment group and the control group were 37.9% and 19.6% respectively;with cavity closure rate of 65.5% in the treatment group and 38.7% in the control group;at the 2^(nd) week,the clinical symptoms such as cough,fever,fatigue disappeared at the level of 48.3%,71.4%,59.3% in the treatment group and of 25.5%,50.0%,40.0% in the control group(P<0.05)respectively;there were no drug adverse reaction in the treatment group;there were no significant difference on the sputum positive conversion rates at the 6^(th),12^(th) and 24^(th) month after treatment between the treatment group and the control(P>0.05).?Conclusion M.Vaccae vaccine combining chemotherapy shortens the time of sputum negative conversion,the resolution of pulmonary lesions and the improvement of clinic symptoms.The drug adverse reaction is slight.It is a fairly good immune drug for TB treatment and is worth to be recommended.

关 键 词：结核 肺/药物治疗 微卡 

分 类 号：R521[医药卫生—内科学]